Listing 3 - Actual negotiations

Indication:

Ulcerative Colitis

Indication:

Cystic fibrosis, F508del CFTR mutation, 2 years and older

Indication:

Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Indication:

Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis)

Indication:

Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes

Indication:

Ulcerative Colitis

Indication:

Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy

Indication:

Chronic lymphocytic leukemia (CLL) in adult patients

Indication:

Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel

Indication:

Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory